- Solazyme (SZYM -1.4%) is at an attractive entry point ahead of its Q4 earnings report next week and an expected ramp-up in production as its relationship with Archer Daniels Midland and Bunge reach full potential, Cowen analysts say.
- The future SZYM's stock hinges on the new Brazil plant: “Other biomaterials firms have stumbled at the final commercialization step, which helps explain the huge rally in SZYM on the news of first shipments from Clinton,” Cowen says.
- Commercial startup has been delayed to Q1 from Q4 2013 for enhancements, and confirmation that the plant will be starting up soon would be “an important trigger for the stock."
Cowen finds Solazyme attractive as production, partnerships grow
Feb 21 2014, 15:58 ET